By Justin Petrone

In response to a patent-infringement suit filed last November, Illumina has denied that its BeadChips and certain other technologies infringe a patent held by privately held drug maker Syntrix.

Illumina has also asked the court to declare that the patent at the heart of the suit is invalid and to dismiss the complaint with prejudice.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.